PropertyValue
is ?:annotates of
?:authorAffiliation
  • [\'Raabe College of Pharmacy, Ohio Northern University, Ada, OH, USA.\', \'System Pharmacy Services, University Hospitals of Cleveland, Cleveland, OH, USA.\', \'Specialty Pharmacy, University Hospitals of Cleveland, Cleveland, OH, USA.\', \'Multiple Sclerosis and Neuroimmunology Program, University Hospitals of Cleveland, Case Western Reserve University School of Medicine, Cleveland Medical Center, Bolwell, 5th Floor, 11100 Euclid Avenue, Cleveland, OH, 44106, USA.\', \'VA Multiple Sclerosis Center of Excellence, Cleveland VA Medical Center, Cleveland, OH, USA.\', \'Multiple Sclerosis and Neuroimmunology Program, University Hospitals of Cleveland, Case Western Reserve University School of Medicine, Cleveland Medical Center, Bolwell, 5th Floor, 11100 Euclid Avenue, Cleveland, OH, 44106, USA. Hesham.abboud@uhhospitals.org.\']
?:citedBy
  • -1
?:creator
?:doi
?:doi
  • 10.1007/s40263-020-00756-y
?:hasPublicationType
?:journal
  • CNS drugs
is ?:pmid of
?:pmid
?:pmid
  • 32780300
?:publication_isRelatedTo_Disease
?:rankingScore_SJR
  • 1.635
?:rankingScore_hIndex
  • 96
is ?:relation_isRelatedTo_publication of
?:title
  • Multiple Sclerosis Disease-Modifying Therapy and the COVID-19 Pandemic: Implications on the Risk of Infection and Future Vaccination.
?:type
?:year
  • 2020

Metadata

Anon_0  
<http://www.w3.org/1999/02/22-rdf-syntax-ns#type> <http://purl.org/net/provenance/ns#DataItem>
<http://www.w3.org/1999/02/22-rdf-syntax-ns#type> <http://www.w3.org/2004/03/trix/rdfg-1/Graph>
<http://xmlns.com/foaf/0.1/primaryTopic> <https://research.tib.eu/covid-19/entity/32780300>
<http://xmlns.com/foaf/0.1/topic> Anon_0
<http://www.ontologydesignpatterns.org/cp/owl/informationrealization.owl#realizes> <https://research.tib.eu/covid-19/data/entity/32780300>
<http://purl.org/net/provenance/ns#createdBy>
Anon_1   (more)
expand all